New updates have been reported about Acurion.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acurion has closed an oversubscribed $4.3 million seed financing round, exceeding its $4 million target to advance its AI-based oncology platform OncoGaze™ from validation toward broader clinical deployment. The round was led by TK & Partners with participation from Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research, Bootstrap Ventures, and other institutional and healthcare-focused investors, providing capital for further clinical validation, platform development, regulatory preparation, and commercialization.
CEO Rick Fultz said the raise underscores investor confidence in Acurion’s strategy to make biomarker detection more accessible, scalable, and actionable in routine care settings, as the company moves quickly from research into real-world clinical use. Built on foundational work by co-founder and CSO Ludmil Alexandrov, Ph.D., at UC San Diego on mutational signatures, OncoGaze™ uses AI-powered image analysis to extract clinically relevant biomarker insights from standard pathology slides, potentially bypassing the cost and delays of traditional genomic testing while expanding access to precision oncology; Acurion reports growing clinical collaborations, publications in leading journals, and plans to announce additional partnerships and regulatory milestones in the coming months.